BACKGROUND: Studies suggest that testosterone (TT) replacement may have an antidepressant effect in depressed patients. OBJECTIVE: The objective of this study was to explore the effect of TT administration on depression using both a systematic review of the literature and a meta-analysis. METHODOLOGY: A search was conducted of MEDLINE, the Clinical Trials Registry, and Cochrane Central for English-language publications concerning randomized, placebo-controlled trials involving use of TT therapy in depressed patients. We searched for additional trials in the individual reference lists of the articles identified in the search. A study was judged to be relevant for inclusion in this review and meta-analysis if it reported original data from a controlled trial comparing use of TT and placebo in patients diagnosed with a depressive disorder according to DSM criteria, and the treatment response was evaluated according to changes on the Hamilton Rating Scale for Depression (HAM-D). We extracted the following data from the identified studies: study source, total number of participants in the study and in each treatment group, participants' ages, number of participants with a diagnosis of hypogonadism or HIV/AIDS, study duration, type of intervention, and change in HAM-D scores in the groups receiving TT versus placebo. The meta-analysis evaluated the effect of TT replacement on response in depressed patients as measured by change in HAM-D scores in the available placebo-controlled, randomized clinical trails. RESULTS: Seven studies (N=364) were identified that included a placebo-control group in a double-blind design. Eligibility criteria were clearly reported in all trials. Meta-analysis of the data from these seven studies showed a significant positive effect of TT therapy on HAM-D response in depressed patients when compared with placebo (z=4.04, P<0.0001). Subgroup analysis also showed a significant response in the subpopulations with hypogonadism (z=3.84, P=0.0001) and HIV/AIDS (z=3.33, P=0.0009) as well as in patients treated with TT gel (z=2.32, P=0.02). CONCLUSIONS: TT may have an antidepressant effect in depressed patients, especially those with hypogonadism or HIV/AIDS and elderly subpopulations. The route by which TT is administered may play a role in treatment response.
BACKGROUND: Studies suggest that testosterone (TT) replacement may have an antidepressant effect in depressedpatients. OBJECTIVE: The objective of this study was to explore the effect of TT administration on depression using both a systematic review of the literature and a meta-analysis. METHODOLOGY: A search was conducted of MEDLINE, the Clinical Trials Registry, and Cochrane Central for English-language publications concerning randomized, placebo-controlled trials involving use of TT therapy in depressedpatients. We searched for additional trials in the individual reference lists of the articles identified in the search. A study was judged to be relevant for inclusion in this review and meta-analysis if it reported original data from a controlled trial comparing use of TT and placebo in patients diagnosed with a depressive disorder according to DSM criteria, and the treatment response was evaluated according to changes on the Hamilton Rating Scale for Depression (HAM-D). We extracted the following data from the identified studies: study source, total number of participants in the study and in each treatment group, participants' ages, number of participants with a diagnosis of hypogonadism or HIV/AIDS, study duration, type of intervention, and change in HAM-D scores in the groups receiving TT versus placebo. The meta-analysis evaluated the effect of TT replacement on response in depressedpatients as measured by change in HAM-D scores in the available placebo-controlled, randomized clinical trails. RESULTS: Seven studies (N=364) were identified that included a placebo-control group in a double-blind design. Eligibility criteria were clearly reported in all trials. Meta-analysis of the data from these seven studies showed a significant positive effect of TT therapy on HAM-D response in depressedpatients when compared with placebo (z=4.04, P<0.0001). Subgroup analysis also showed a significant response in the subpopulations with hypogonadism (z=3.84, P=0.0001) and HIV/AIDS (z=3.33, P=0.0009) as well as in patients treated with TT gel (z=2.32, P=0.02). CONCLUSIONS:TT may have an antidepressant effect in depressedpatients, especially those with hypogonadism or HIV/AIDS and elderly subpopulations. The route by which TT is administered may play a role in treatment response.
Authors: Huanguang Jia; Charles T Sullivan; Sean C McCoy; Joshua F Yarrow; Matthew Morrow; Stephen E Borst Journal: World J Clin Cases Date: 2015-04-16 Impact factor: 1.337
Authors: William E Copeland; Carol Worthman; Lilly Shanahan; E Jane Costello; Adrian Angold Journal: J Am Acad Child Adolesc Psychiatry Date: 2019-02-14 Impact factor: 8.829
Authors: C Xu; X Ju; D Song; F Huang; D Tang; Z Zou; C Zhang; T Joshi; L Jia; W Xu; K-F Xu; Q Wang; Y Xiong; Z Guo; X Chen; F Huang; J Xu; Y Zhong; Y Zhu; Y Peng; L Wang; X Zhang; R Jiang; D Li; T Jiang; D Xu; C Jiang Journal: Mol Psychiatry Date: 2014-09-09 Impact factor: 15.992
Authors: Matthew S Panizzon; Richard Hauger; Hong Xian; Eero Vuoksimaa; Kelly M Spoon; Sally P Mendoza; Kristen C Jacobson; Terrie Vasilopoulos; Brinda K Rana; Ruth McKenzie; Jeanne M McCaffery; Michael J Lyons; William S Kremen; Carol E Franz Journal: Neurobiol Aging Date: 2013-12-27 Impact factor: 4.673
Authors: Thiago Gagliano-Jucá; Thomas G Travison; Paul L Nguyen; Philip W Kantoff; Mary-Ellen Taplin; Adam S Kibel; Robert Manley; Kathleen Hally; Richelle Bearup; Yusnie M Beleva; Grace Huang; Robert R Edwards; Shehzad Basaria Journal: J Pain Symptom Manage Date: 2017-09-21 Impact factor: 3.612